Verrica Pharmaceuticals Inc’s filing revealed that its CHIEF LEGAL OFFICER Hayes Christopher G. unloaded Company’s shares for reported $69647.0 on Aug 26 ’24. In the deal valued at $2.66 per share,26,183 shares were sold. As a result of this transaction, Hayes Christopher G. now holds 115,303 shares worth roughly $0.15 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, Hayes Christopher G. sold 9,530 shares, generating $23,444 in total proceeds. Upon selling the shares at $2.46, the CHIEF LEGAL OFFICER now owns 105,773 shares.
Before that, Goldenberg Gary sold 9,888 shares. Verrica Pharmaceuticals Inc shares valued at $26,302 were divested by the Chief Medical Officer at a price of $2.66 per share. As a result of the transaction, Goldenberg Gary now holds 97,862 shares, worth roughly $0.13 million.
Needham upgraded its Verrica Pharmaceuticals Inc [VRCA] rating to a Buy from a a Hold in a research note published recently. A number of analysts have revised their coverage, including Jefferies’s analysts, who began to cover the stock in late March with a ‘”a Buy”‘ rating. RBC Capital Mkts also remained covering VRCA and has increased its forecast on February 13, 2023 with a “an Outperform” recommendation from previously “Sector perform” rating. RBC Capital Mkts revised its rating on May 25, 2022. It rated VRCA as “a Sector perform” which previously was an “an Outperform”.
Price Performance Review of VRCA
On Monday, Verrica Pharmaceuticals Inc [NASDAQ:VRCA] saw its stock jump 2.29% to $1.34. Over the last five days, the stock has lost -7.59%. Verrica Pharmaceuticals Inc shares have fallen nearly -81.69% since the year began. Nevertheless, the stocks have fallen -65.99% over the past one year. While a 52-week high of $11.41 was reached on 05/14/24, a 52-week low of $1.04 was recorded on 10/02/24. SMA at 50 days reached $2.9630, while 200 days put it at $5.8128.
Levels Of Support And Resistance For VRCA Stock
The 24-hour chart illustrates a support level at 1.2533, which if violated will result in even more drops to 1.1667. On the upside, there is a resistance level at 1.4433. A further resistance level may holdings at 1.5467. The Relative Strength Index (RSI) on the 14-day chart is 30.36, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.2169, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 68.81%. Stochastics %K at 33.79% indicates the stock is a holding.
How much short interest is there in Verrica Pharmaceuticals Inc?
A steep rise in short interest was recorded in Verrica Pharmaceuticals Inc stocks on 2024-09-13, dropping by -0.94 million shares to a total of 3.25 million shares. Yahoo Finance data shows the prior-month short interest on 2024-08-15 was 4.19 million shares. There was a decline of -28.78%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on May 14, 2021 when RBC Capital Mkts began covering the stock and recommended ‘”an Outperform”‘ rating along with a $19 price target.
